Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Core Scientific (CORZ) Current Deferred Revenue (2021 - 2026)

Core Scientific has reported Current Deferred Revenue over the past 6 years, most recently at $654.2 million for Q1 2026.

  • Quarterly results put Current Deferred Revenue at $654.2 million for Q1 2026, up 974.26% from a year ago — trailing twelve months through Mar 2026 was $654.2 million (up 974.26% YoY), and the annual figure for FY2025 was $555.9 million, up 2965.24%.
  • Current Deferred Revenue reached $654.2 million in Q1 2026 per CORZ's latest filing, up from $555.9 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $654.2 million in Q1 2026 and bottomed at $2.5 million in Q3 2025.
  • Median Current Deferred Revenue over the past 5 years was $69.3 million (2022), compared with a mean of $142.5 million.
  • The largest annual shift saw Current Deferred Revenue crashed 87.35% in 2023 before it skyrocketed 2965.24% in 2025.
  • Over 5 years, Current Deferred Revenue stood at $77.7 million in 2022, then plummeted by 87.35% to $9.8 million in 2023, then surged by 84.48% to $18.1 million in 2024, then surged by 2965.24% to $555.9 million in 2025, then rose by 17.7% to $654.2 million in 2026.
  • Business Quant data shows Current Deferred Revenue for CORZ at $654.2 million in Q1 2026, $555.9 million in Q4 2025, and $2.5 million in Q3 2025.